Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Josep-María Cendrós"'
Autor:
Concepción Peraire, Joaquim Ramis, Rosendo Obach, Iñaki F. Trocóniz, Josep-María Cendrós, María J. Garrido
Publikováno v:
The Journal of Clinical Pharmacology. 52:487-498
Acromegaly arises from excessive levels of growth hormone (GH), many of whose effects are mediated by stimulation of secretion of insulin-like growth factor 1 (IGF-1). Synthetic somatostatin analogues inhibit GH secretion. The objective of the study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb3ed6de0c6b21573d998add052fadcc
https://doi.org/10.1177/0091270011399761
https://doi.org/10.1177/0091270011399761
Publikováno v:
Cancer Chemotherapy and Pharmacology. 63:945-952
Diflomotecan, a homocamptothecin, targets DNA topoisomerase I. Previous clinical trials have demonstrated a variable degree of dose limiting toxicity. The purpose of this study was to further evaluate the safety and pharmacokinetic profile of a range
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d753f7dda84000336b98824e2a4a20aa
https://doi.org/10.1007/s00280-008-0795-6
https://doi.org/10.1007/s00280-008-0795-6
Autor:
Iñaki F. Trocóniz, Rosendo Obach, Cristina Segura, Concepción Peraire, María J. Garrido, Josep-María Cendrós, Paola Principe
Publikováno v:
Cancer Chemotherapy and Pharmacology. 57:727-735
Purpose: To determine the maximum tolerated dose (MTD) of intravenous (iv) diflomotecan administered once every 3 weeks, and to characterize the relationship between pharmacokinetics and neutropenic effect, using a semi-mechanistic pharmacokinetic/ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ba56f04dc028cce0b4b14a8c416d550
https://doi.org/10.1007/s00280-005-0112-6
https://doi.org/10.1007/s00280-005-0112-6
Publikováno v:
Veterinary Medicine and Science, Vol 8, Iss 1, Pp 31-45 (2022)
Abstract Enflicoxib is a newly developed NSAID of the coxib class. The optimal therapeutic dose to be confirmed in the field studies was established using a combination of pharmacokinetic (PK) modelling and pharmacodynamic (PD) studies. First, a PK s
Externí odkaz:
https://doaj.org/article/3964c3804fb44396812d9e5b21933afd
Autor:
Concepción Peraire, Nieves Velez de Mendizabal, Elba Romero, Emma Bascompta, Josep-María Cendrós, Iñaki F. Trocóniz, Rosendo Obach
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 342(3)
The objectives of the current work were to develop a predictive population pharmacokinetic (PK)/pharmacodynamic (PD) model for the testosterone (TST) effects of triptorelin (TRP) administered in sustained-release (SR) formulations to patients with pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bda5d7aa8591f02af97c2200f243ef6b
https://pubmed.ncbi.nlm.nih.gov/22691297
https://pubmed.ncbi.nlm.nih.gov/22691297
Autor:
Ron J. Keizer, Iñaki F. Trocóniz, Mats O. Karlsson, Elena Soto, Rosendo Obach, Lena E. Friberg, Jan H.M. Schellens, Concepción Peraire, Jos H. Beijnen, Josep María Cendrós, Alwin D. R. Huitema, Jantien Wanders
Publikováno v:
Investigational New Drugs
Summary In cancer chemotherapy neutropenia is a common dose-limiting toxicity. An ability to predict the neutropenic effects of cytotoxic agents based on proposed trial designs and models conditioned on previous studies would be valuable. The aim of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67ad4bc0a4177883423963b113450e7d
https://pubmed.ncbi.nlm.nih.gov/20449627
https://pubmed.ncbi.nlm.nih.gov/20449627
Autor:
Helena Colom, Dolors Soy, Josep Domenech, Concepción Peraire, Nuria Pardo, Rosa Farré, Josep-María Cendrós, Montserrat Torrent, Maria-Antonia Mangues
Publikováno v:
THERAPEUTIC DRUG MONITORING
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
The goal of this study was to establish the population pharmacokinetics (PK) of high-dose methotrexate (HD-MTX) treatment in children with osteosarcoma and to explore the influence of patient covariates and between-occasion variability on drug dispos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::270578b66c0df4b9a6e74f8294fc4c94
https://pubmed.ncbi.nlm.nih.gov/19077931
https://pubmed.ncbi.nlm.nih.gov/19077931
Autor:
Paolo F. Boscani, María J. Garrido, Joaquiln Ramis, Iñaki F. Trocóniz, Rosendo Obach, Concepción Peraire, Josep-María Cendrós
Publikováno v:
Clinical pharmacokinetics. 48(1)
Lanreotide is a somatostatin analogue used for the treatment of acromegaly and neuroendocrine tumours. The objective of this study was to develop a pharmacokinetic model for the sustained-release formulation lanreotide Autogel after deep subcutaneous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f573ed8fde560191e752d8b0fed0890e
https://pubmed.ncbi.nlm.nih.gov/19071884
https://pubmed.ncbi.nlm.nih.gov/19071884
Autor:
A. Leselbaum, Joaquim Ramis, Nina R. C. Musolino, Raquel S. Jallad, F. Catus, Josep-María Cendrós, Marcello D. Bronstein, Rosendo Obach
Publikováno v:
Clinical endocrinology. 63(5)
Summary Objective To investigate the pharmacokinetic profile of a prolonged release, aqueous Autogel® formulation of the somatostatin analogue lanreotide (Lan-ATG). Design A phase II, randomized, double-blind study, during which patients received 60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c5773a9ceff7cb197d31509aaf0ce18
https://pubmed.ncbi.nlm.nih.gov/16268802
https://pubmed.ncbi.nlm.nih.gov/16268802